Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc

Bullboard Posts

Comment by pabalooon Apr 26, 2020 7:01pm

39 Views

Post# 30955667

RE:RE:RE:RE:RE:RE:RE:RE:RE:Trevyent News and Quarter Results Coming Soon

Hey penny pincher tell me more about the three card monte guy. He's running a company that made 10 cents American last quarter zero debt and a product that Bausch would love to distribute in Canada. Doubtful about Cipher paying them anything maybe 15 million will get them the rights

Bullboard Posts

Three stocks with strong income statements to buy right now